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ABSTRACT
OBJECTIVES
To investigate whether the use of graduated 
compression stockings (GCS) offers any adjuvant 
benefit when pharmaco-thromboprophylaxis is used 
for venous thromboembolism prophylaxis in patients 
undergoing elective surgery.
DESIGN
Open, multicentre, randomised, controlled, non-
inferiority trial.
SETTING
Seven National Health Service tertiary hospitals in the 
United Kingdom.
PARTICIPANTS
1905 elective surgical inpatients (≥18 years) 
assessed as being at moderate or high risk of venous 
thromboembolism were eligible and consented to 
participate.
INTERVENTION
Participants were randomly assigned (1:1) to receive 
low molecular weight heparin (LMWH) pharmaco-
thromboprophylaxis alone or LMWH pharmaco-
thromboprophylaxis and GCS.
OUTCOME MEASURES
The primary outcome was imaging confirmed lower limb 
deep vein thrombosis with or without symptoms, or 
pulmonary embolism with symptoms within 90 days of 
surgery. Secondary outcome measures were quality of 
life, compliance with stockings and LMWH, lower limb 
complications related to GCS, bleeding complications, 
adverse reactions to LMWH, and all cause mortality.
RESULTS
Between May 2016 and January 2019, 1905 
participants were randomised. 1858 were included 
in the intention to treat analysis (17 were identified 
as ineligible after randomisation and 30 did not 
undergo surgery). A primary outcome event occurred 
in 16 of 937 (1.7%) patients in the LMWH alone 
group compared with 13 of 921 (1.4%) in the LMWH 
and GCS group. The risk difference between the two 
groups was 0.30% (95% confidence interval −0.65% 
to 1.26%). Because the 95% confidence interval did 
not cross the non-inferiority margin of 3.5% (P<0.001 
for non-inferiority), LMWH alone was confirmed to be 
non-inferior.
CONCLUSIONS
For patients who have elective surgery and are at 
moderate or high risk of venous thromboembolism, 
administration of pharmaco-thromboprophylaxis 
alone is non-inferior to a combination of pharmaco-
thromboprophylaxis and GCS. These findings indicate 
that GCS might be unnecessary in most patients 
undergoing elective surgery.
TRIAL REGISTRATION
Trial registration
ISRCTN13911492.
Introduction
Venous thromboembolism (VTE) is a major global 
health problem and an important consideration for 
patients and clinicians at the time of elective surgery. 
Before elective surgical procedures, patients undergo a 
VTE risk assessment to guide the use of mechanical and 
pharmaco-thromboprophylaxis measures. Evidence 
exists for the use of pharmaco-thromboprophylaxis 
and graduated compression stockings (GCS) as 
mechanical thromboprophylaxis in this patient group.1 
A systematic review and meta-analysis of 20 trials in 
surgical patients demonstrated much lower rates of 
deep vein thrombosis in patients randomised to GCS 
(134/1365, 9.8%) compared with those in control 
groups (282/1328, 21.2%)2; however, 19 of these 
trials were conducted before the year 2000. Rates of 
VTE have fallen over the past 50 years, partly because 
of thromboprophylaxis but also owing to changes in 
clinical practice.3 Therefore, the effectiveness of GCS 
in modern practice is uncertain. In surgical patients, 
use of low molecular weight heparin (LMWH) reduces 
clinical VTE and VTE without symptoms.4 Current 
guidelines widely recommend VTE prevention in the 
absence of contraindications by using a combination 
of GCS and pharmaco-thromboprophylaxis for 
patients undergoing elective surgery who are at 
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Venous thromboembolism prophylaxis is needed in most patients undergoing 
surgical procedures
The adjuvant benefit of graduated compression stockings in addition to 
pharmaco-thromboprophylaxis in these patients is unclear
WHAT THIS STUDY ADDS
This trial showed that in patients who had elective surgical procedures and were 
assessed to be at moderate or high risk of venous thromboembolism, pharmaco-
thromboprophylaxis alone is non-inferior to pharmaco-thromboprophylaxis and 
graduated compression stockings
Current guidelines based on historical data should be revised
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moderate or high risk of VTE. In the United Kingdom, 
the Department of Health VTE risk assessment tool is 
advocated (https://www.nice.org.uk/guidance/ng89/
resources/department-of-health-vte-risk-assessment-
tool-pdf-4787149213),5 whereas internationally, the 
Caprini risk assessment tool (https://venousdisease.
com/caprini-dvt-risk-assessment/) is also used to 
determine patients’ risk of VTE.6 7
The effectiveness of GCS in modern practice has 
been questioned.8 A large randomised controlled 
trial in patients with stroke showed increased 
adverse events with GCS without an accompanying 
benefit in VTE reduction.9 In the context of elective 
surgery, a systematic review10 identified only one 
study in patients undergoing orthopaedic surgery 
that evaluated the benefit of GCS in addition to 
pharmaco-thromboprophylaxis. This single study 
found no additional benefit in using GCS.11 The review 
concluded that quantitative comparison or drawing 
definitive conclusions was difficult.10
We performed the graduated compression as an 
adjunct to pharmaco-thromboprophylaxis in surgery 
(GAPS) study,12 a large, pragmatic, multicentre, 
clinical effectiveness, two arm, parallel group, 
randomised controlled non-inferiority trial. In 
this study we evaluated the addition of GCS to 
LMWH for VTE prevention in patients undergoing 
elective surgery. Our aim was to investigate whether 
thromboprophylactic dose LMWH alone was non-
inferior to thromboprophylactic dose LMWH and GCS 
in preventing imaging confirmed lower limb deep vein 
thrombosis with or without symptoms, or pulmonary 
embolism with symptoms up to 90 days after surgery.
Methods
Study design
Between May 2016 and January 2019, we enrolled 
participants in this randomised, non-inferiority 
clinical trial at seven centres across the UK 
(supplementary appendix). Details of the trial 
design and implementation are provided in the 
protocol, which has been published previously.12 
All participants provided written informed consent 
and a trial steering committee and independent data 
monitoring committee provided the study oversight.
Participants
Patients aged 18 years and older who were undergoing 
elective surgery and were assessed as being at 
moderate risk (score 1) or high risk (score ≥2) of VTE 
using the Department of Health VTE risk assessment 
tool5 (supplementary figure, web appendix 3) were 
screened for eligibility. We also assessed the VTE risk 
by using the Caprini risk assessment tool to evaluate 
applicability worldwide.7 We excluded female patients 
if they were pregnant, and any patients if LMWH or 
GCS were contraindicated, if they had a thrombophilia 
or thrombotic disorder, if they required therapeutic 
anticoagulation, or if they had a history of VTE. We also 
excluded patients if they required inferior vena cava 
filter insertion, intermittent pneumatic compression 
beyond the post anaesthesia recovery area, extended 
thromboprophylaxis (beyond discharge), or if they 
needed a cast or brace to be applied in the operating 
theatre. All participants provided written informed 
consent.
Changes to study design
Because of the low event rate (blinded analysis 
on 1294 participants) and after input from the 
trial steering committee and independent data 
monitoring committee, the study design was revised in 
December 2017 (full details in the study protocol and 
supplementary appendix) to stratify the recruitment 
by age (<65 or ≥65 years) and VTE risk (moderate or 
high). We abandoned the group sequential design and 
respecified appropriate non-inferiority for these four 
subpopulations. Findings are reported for the original 
unstratified sample and the revised stratified sample.
Randomisation and masking
Participants were randomised 1:1 to either pharmaco-
thromboprophylaxis using LMWH alone or LMWH 
and GCS before they had surgery. Randomisation 
was through a web based application hosted by 
the University of Aberdeen Centre for Healthcare 
Randomised Trials. We used a minimisation algorithm 
that incorporated centre, moderate or high risk of 
VTE (VTE risk was not included after December 2017 
because all participants recruited after this date 
were at high risk) and sex; a random element was 
also incorporated. Participants and investigators 
Visual Abstract Are compression stockings unnecessary?
Use as an adjunct to pharmaco-thromboprophylaxis in surgery
Within the study population, pharmaco-thromboprophylaxis alone 
is non-inferior to a combination of pharmaco-thromboprophylaxis 
plus graduated compression stockings
Summary
1888
participants
Population Venous thromboembolismrisk at baseline:
Moderate: 15.9%, High: 84.1%
Adult elective 
surgical 
inpatients
63.3%
women
*  included in analysis
†  included in analysis
© 2020 BMJ Publishing group Ltd.http://bit.ly/BMJcstock
Primary outcome
Venous thromboembolism: imaging confirmed lower limb deep 
vein thrombosis with or without symptoms, or pulmonary 
embolism with symptoms within  days of surgery
Significance
Prespecified non-inferiority
margin of .%
Study design Randomised controlled trial
Randomisation allocation was :
between intervention and control
Single
blinded 
Comparison Intervention
948*
Control Standard care
940†
Low molecular weight heparin only Low molecular weight heparin and
graduated compression stockings
1.7% 1.4%
Outcomes
Venous thromboembolism occurrence 0.30   -0.65 to 1.26;
P<0.001 for non-inferiority
Risk difference, %  % CI
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were not masked to treatment allocation. Vascular 
scientists or technologists who performed the duplex 
ultrasound scans were blinded to the study allocation. 
Participants were asked to remove their stockings and 
not to disclose their treatment allocation to staff who 
performed the scan.
Interventions
Participants in both study groups were given 
thromboprophylactic doses of LMWH for the period 
of hospital admission. The formulation of LMWH 
varied by centre, however dosing was the standard 
manufacturer’s thromboprophylactic dose for the 
formulation. Participants randomised to adjuvant GCS 
received above or below knee GCS (providing 18 mm 
Hg compression at the level of the ankle) in addition 
to LMWH. Participants were asked to wear GCS for 
the duration of hospital admission. The brand and 
length of GCS supplied was guided by local standard 
policies. Previous studies have shown below knee GCS 
to be comparable to full length GCS in preventing deep 
vein thrombosis.13 Participants randomised to LMWH 
alone were asked not to wear any kind of compression 
stocking for 90 days after surgery.
Outcomes
The primary outcome was new VTE within 90 days of 
surgery, either lower limb deep vein thrombosis with 
or without symptoms, proven by duplex ultrasound, 
or pulmonary embolism with symptoms confirmed 
by imaging. Participants were invited to undergo 
a bilateral full lower limb duplex ultrasound scan 
between 14 and 21 days after surgery to capture 
the peak incidence of VTE.14 15 Whole leg venous 
ultrasound scans were performed, which evaluated 
deep veins from the common femoral vein to calf veins. 
Symptoms suggestive of VTE could trigger imaging at 
any point during the trial. If a positive diagnosis was 
made, the treating clinical team and local principal 
investigator were informed and the patient was treated 
in accordance with local hospital guidelines. An 
anonymised copy of the scan report was sent to the 
trial coordinating centre where the primary outcome 
was verified by an independent blinded clinical expert. 
The 90 day endpoint is in line with the definition of 
hospital acquired thrombosis.16-18 Secondary outcome 
measures included quality of life (assessed by using 
EQ-5D-5L (EuroQol five dimensions five levels)), 
compliance with stockings and LMWH, GCS related 
lower limb complications, bleeding complications, 
adverse reactions to LMWH, and all cause mortality.
Statistical analysis
The supplementary material gives full details of the 
original and revised sample size calculations. The 
original sample size was 2236 for the primary outcome 
of VTE at 90 days. This sample was intended to have 
90% power at a one sided 2.5% level of significance 
to detect a 3.5% non-inferiority margin (considered to 
be clinically important) over an assumed 6% event rate 
in the group randomised to LMWH and GCS; this rate 
was adjusted for 10% loss to follow up and the group 
sequential design. We derived the imaging confirmed 
VTE event rate of 6% from a recent systematic review 
that identified randomised controlled trials with 
arms exploring VTE outcomes in patients who had 
elective surgery.10 This margin was chosen because 
clinicians would not tolerate more than 3.5% absolute 
deterioration in VTE event rate over combination 
therapy. The margin also preserves 61% of the 
established treatment effect over no intervention. 
When we stratified patients by age (<65 or ≥65 years) 
and VTE risk category (moderate or high risk), four 
subpopulations were identified.
The formal interim analyses in the group sequential 
design were specified in event time; that is, after 
several events had accumulated. After the trial steering 
committee identified an overall lower than anticipated 
event rate, the independent data monitoring committee 
were unable to perform their first planned analysis. 
Instead the blinded senior statistician performed 
a blinded analysis of the first 1294 randomised 
patients, which identified a group in which the event 
rate was higher. We recalculated the sample sizes for 
four subpopulations stratified by age and VTE risk, 
abandoning the group sequential design. For example, 
in the group of patients aged 65 years and older, who 
were assessed as being at high VTE risk, we needed 912 
participants, which would allow detection of a 4.0% 
non-inferiority margin assuming a 3.6% control rate.
We analysed VTE risk within 90 days of surgery by 
generalised linear modelling adjusted for sex and we 
added a cluster robust error for centre. Both intention 
to treat and per protocol analyses were performed, 
which included only participants who received the 
intervention to which they were randomised. We 
used the upper limit of the two sided 95% confidence 
interval for the risk difference to infer non-inferiority. A 
non-inferiority P value was calculated. We performed 
sensitivity analyses by only including participants 
who had a duplex scan and separately including 
post-randomisation exclusions. Similar analyses 
were performed for the four subpopulations unless a 
zero event rate existed in each arm, when a one sided 
absolute incidence confidence interval was reported.
EQ-5D-5L data were analysed using a mixed effects 
repeated measures model adjusted for baseline score, 
VTE risk, sex, and a random effect for centre. We 
performed non-parametric bounds19 for the average 
causal effect for compliance with stockings and LMWH. 
Participants were classified as fully compliant with 
LMWH if they received all prescribed LMWH doses, and 
partially compliant when they received more than 50% 
of prescribed doses. Compliance with GCS was defined 
as good if participants wore stockings for at least 75% 
of their hospital admission. Because of the low number 
of events, no formal analyses were planned for GCS 
related complications, adverse reactions to LMWH, 
bleeding complications, and all cause mortality. The 
subpopulations were analysed in a similar way.
We performed a post hoc analysis of the Caprini 
score for the overall trial population by using a 
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generalised linear model that adjusted for sex and 
we added a cluster robust error for centre. For our 
analysis, the Caprini score was categorised as low-high 
(score <5) and highest (score ≥5) owing to the small 
number of participants in some of the categories. We 
excluded participants from all analyses if they did not 
undergo surgery. All analyses were performed in Stata 
version 15.20
Patient and public involvement
A member of the registered charity Thrombosis UK 
acted as patient representative, assisting from the 
grant writing stages through to study completion. She 
also sat on the trial steering committee, which made 
all the major decisions from the planning and design, 
to approving study amendments, and assisting with 
dissemination of the study results to study participants 
and the general public.
Results
Screening
Of the 11 679 participants screened, 1905 were 
randomised with 17 classed as having post 
randomisation exclusions (fig 1 and table S2). 
Therefore, 1888 participants were included (948 in 
LMWH alone group and 940 in LMWH and GCS group). 
Of these, 1858 had surgery (937 in LMWH alone group 
and 921 in LMWH and GCS group) and were included 
in the intention to treat analysis. Table S3 presents 
details of participants in each subpopulation and table 
Patients screened
Excluded
Ineligible
Declined
Patients missed
6690
1780
1304
Received surgery
Did not receive surgery
Surgical plans changed
Surgery rescheduled aer end of study
Patient refused surgery
Died prior to surgery
937
11
3
5
2
1
Received surgery
Did not receive surgery
Surgical plans changed
Surgery rescheduled aer end of study
Patient refused surgery
Withdrew before surgery
Moved away
921
19
6
3
5
4
1
Randomised
Included in analysis Included in analysis
LMWH LMWH + GCS
1905
940
Withdrawn0 Died0
Initial follow-up
921
Withdrawn0 Died0
Initial follow-up
937
921937
Withdrawn0 Died0
14-21 day follow-up
767
Withdrawn0 Died0
14-21 day follow-up
810
Withdrawn0 Died1
90 day follow-up
920
Withdrawn2 Died2
90 day follow-up
933
948
9774
Post randomisation exclusions
LMWH
LMWH + GCS
6
11
11 679
17
Fig 1 | CONSORT (Consolidated Standards of Reporting Trials) diagram showing assessment of eligibility, enrolment, 
and follow-up
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S1 gives reasons why participants were ineligible or 
declined to participate.
Baseline characteristics were similar in both groups 
(table 1 and table S4) and in the four subpopulations 
(table S5). Elective surgery was performed in 937/948 
(98.8%) participants randomised to LMWH alone 
and 921/940 (98.0%) randomised to LMWH and GCS 
(table S6). The most common surgical procedures 
were general (upper gastrointestinal), obstetrics and 
gynaecology, and general (lower gastrointestinal; 
table S6). The allocated intervention was delivered 
in 758/948 (80.0%) in the LMWH alone group and 
750/940 (79.8%) in the LMWH and GCS group (tables 
S6 and S7). In the LMWH and GCS group, 892/940 
(94.9%) participants received GCS, of which 854/892 
(95.7%) were below knee (tables S6 and S7).
Primary outcome
In the prespecified intention to treat analysis, VTE 
occurred in 16/937 (1.7%) participants in the LMWH 
alone group compared with 13/921 (1.4%) in the 
LMWH and GCS group (risk difference 0.30%, 95% 
confidence interval −0.65% to 1.26%; P<0.001 for 
non-inferiority; fig 2). Because the 95% confidence 
interval did not cross the non-inferiority margin of 
3.5%, the group randomised to LMWH alone was 
demonstrated to be non-inferior. Imaging confirmed 
pulmonary embolism occurred in 2/937 (0.2%) 
participants in the LMWH alone group compared with 
1/921 (0.1%) in the LMWH and GCS group. Deep vein 
thrombosis with symptoms occurred in 2/937 (0.2%) 
participants in the LMWH alone group compared 
with 1/921 (0.1%) in the LMWH and GCS group. In 
patients who had full lower limb duplex imaging, deep 
vein thrombosis without symptoms was identified in 
12/810 (1.5%) participants in the LMWH alone group 
compared with 11/767 (1.4%) in the LMWH and GCS 
group (table 2).
Results were similar in the per protocol analysis 
(LMWH alone 12/758 (1.6%), LMWH and GCS 12/750 
(1.6%); fig 2) and the sensitivity analysis (table S8). 
Non-inferiority for LMWH alone was shown in all the 
subpopulations (fig 2 and table S9).
Secondary outcomes
We found no differences in quality of life outcomes 
between groups at baseline, at one week or discharge 
from hospital, at 14-21 days, or at 90 days (table 3). 
Overall 750/940 (79.8%) participants randomised to 
LMWH and GCS had good compliance with stockings 
(table 3). Full compliance with LMWH was achieved 
in 768/948 (81.0%) in the LMWH alone group and 
in 755/940 (80.3%) in the LMWH and GCS group 
(table 3).
Table 4 summarises complications and all 
cause mortality by treatment received. GCS related 
complications were reported in 50/787 (6.4%) 
patients who received LMWH and GCS, and in 5/160 
(3.1%) patients who received GCS only; most of these 
complications were discomfort. Adverse reactions to 
LMWH were reported in 6/779 (0.8%) patients who 
received LMWH alone and in 2/787 (0.3%) patients 
who received LMWH and GCS (table 4). Two (0.3%) 
deaths occurred in patients who received LMWH 
alone and in 1/132 (0.8%) patient who received no 
treatment; all deaths were unrelated to either LMWH 
or GCS. Serious adverse events (n=239) were reported 
in 210 participants; eight events were considered to be 
probably related to LMWH (table 4 and table S10).
When we used the Caprini score in place of the 
Department of Health VTE risk assessment in a post 
hoc analysis, 1286/1888 (68.1%) participants were 
classified at highest risk of VTE (score ≥5). On intention 
to treat analysis, for patients who had surgery, 14/640 
(2.2%) VTE episodes occurred in the LMWH alone 
group compared with 12/625 (1.9%) in the LMWH and 
GCS group (risk difference 0.27%, 95% confidence 
interval −1.09% to 1.64%, P<0.001 for non-inferiority) 
(fig 2 and table S11).
Discussion
Principal findings
This multicentre, pragmatic randomised study showed 
that pharmaco-thromboprophylaxis with LMWH alone 
is non-inferior to pharmaco-thromboprophylaxis with 
LMWH and GCS in patients who had elective surgery 
and were assessed as being at moderate or high risk 
of VTE. This finding was sustained when we examined 
subpopulations based on age (<65 or ≥65 years) and 
baseline VTE risk (moderate or high).
Table 1 | Baseline characteristics of study participants in the overall population. Values 
are numbers (percentages) unless stated otherwise
Characteristic LMWH (n=948) LMWH+GCS (n=940)
Age (years) (mean (SD)) 59.3 (15.2) 58.1 (14.9)
Sex
 Male 347 (36.6) 346 (36.8)
 Female 601 (63.4) 594 (63.2)
Body mass index (mean (SD)) 28.7 (5.9) 29.0 (6.1)
VTE risk
 Moderate (score 1) 151 (15.9) 150 (16.0)
 High (score ≥2) 797 (84.1) 790 (84.0)
Bleeding risk
 No bleeding risk 918 (96.8) 911 (96.9)
 One or more risk factors 30 (3.2) 29 (3.1)
Caprini risk
 Low (score 0-1) 4 (0.4) 5 (0.5)
 Moderate (score 2) 23 (2.4) 28 (3.0)
 High (score 3-4) 275 (29.0) 267 (28.4)
 Highest (score ≥5) 646 (68.1) 640 (68.1)
EQ-5D-5L* (mean (SD)) 0.825 (0.185) 0.817 (0.192)
EQ-5D VAS† (mean (SD)) 76.9 (17.5) 77.0 (18.1)
Oral contraceptives (women only)
 Yes 16/601 (2.7) 24/594 (4.0)
 No 584/601 (97.2) 570/594 (96.0)
 Missing 1/601 (0.2) 0/594 (0)
Hormone replacement therapy (women only)
 Yes 35/601 (5.8) 39/594 (6.6)
 No 565/601 (94.0) 555/594 (93.4)
 Missing 1/601 (0.2) 0/594 (0)
History of malignancy 213 (22.5) 197 (21.0)
EQ-5D-5L=EuroQol five dimensions five levels; EQ-5D VAS=EuroQol five dimensions visual analogue scale; 
GCS=graduated compression stockings; LMWH=low molecular weight heparin.
No significant differences existed between trial groups.
*LMWH n=942; LMWH+GCS n=926.
†LMWH n=941; LMWH+GCS n=923.
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Strengths and weaknesses of the study
The case mix of elective surgical procedures included 
in this study is similar to the proportions undertaken 
nationally within the UK. Therefore, the results 
appear to be applicable to the wider elective surgical 
population. Most participants in this trial were 
deemed to be in the highest risk category for VTE, 
whether assessed using the Department of Health risk 
assessment tool5 or the Caprini score.7
We acknowledge that our study has limitations. 
Firstly, 281/1858 (15.1%) of participants did not 
receive a duplex ultrasound scan, which could have 
detected more patients with deep vein thrombosis 
without symptoms. However, the proportion was 
relatively small and numbers of missed scans were 
comparably distributed across the two randomised 
groups. The proportion that did not receive a duplex 
ultrasound scan would have been expected to 
contribute approximately one additional asymptomatic 
event to each treatment group, and therefore would 
probably not have influenced the overall findings. 
Secondly, the subgroup of participants aged 65 years 
and older assessed as being at moderate VTE risk was 
underrepresented in the study, which reflects that this 
group is underrepresented in the general population. 
In fact, 797/948 (84.1%) participants in the LMWH 
alone group and 790/940 (84.0%) in the LMWH and 
GCS group were assessed as being high risk (score ≥2) 
for VTE according to the Department of Health VTE risk 
assessment tool. Additionally, more than two thirds of 
participants were highest risk (score ≥5) when assessed 
by using the Caprini score, with non-inferiority of 
LMWH alone compared with LMWH and GCS in these 
highest risk populations.
Comparison to other studies
The results of our study add to a growing body of 
evidence that does not support the use of GCS when 
Table 2 | Details on type of venous thromboembolism in overall population and 
subpopulations. Values are numbers (percentages) unless stated otherwise
Type of VTE LMWH LMWH+GCS
Overall population (LMWH n=937, LMWH+GCS n=921)
VTE within 90 days 16 (1.7) 13 (1.4)
Type of VTE
 DVT with symptoms 2 (12.5) 1 (7.7)
 DVT without symptoms identified by duplex 12 (75.0) 11 (84.6)
 Imaging confirmed pulmonary embolism with symptoms 2 (12.5) 1 (7.7)
Including exclusions after randomisation (LMWH n=943, LMWH+GCS n=932)
VTE within 90 days 16 (1.7) 13 (1.4)
Type of VTE
 DVT with symptoms 2 (12.5) 1 (7.7)
 DVT without symptoms identified by duplex 12 (75.0) 11 (84.6)
 Imaging confirmed pulmonary embolism with symptoms 2 (12.5) 1 (7.7)
Including patients who had a duplex scan (LMWH n=810, LMWH+GCS n=767)
VTE within 90 days 16 (2.0) 13 (1.7)
Type of VTE
 DVT with symptoms 2 (12.5) 1 (7.7)
 DVT without symptoms identified by duplex 12 (75.0) 11 (84.6)
 Imaging confirmed pulmonary embolism with symptoms 2 (12.5) 1 (7.7)
<65 years with high VTE risk (LMWH n=360, LMWH+GCS n=395)
VTE within 90 days 2 (0.6) 1 (0.3)
Type of VTE
 DVT with symptoms 0 (0) 1 (100.0)
 DVT without symptoms identified by duplex 2 (100.0) 0
DVT=deep vein thrombosis; GCS=graduated compression stockings; LMWH=low molecular weight heparin; 
VTE=venous thromboembolism.
DoH risk assessment
  Overall population
     Intention to treat
    Per protocol
  <65 years with high VTE risk
    Intention to treat
    Per protocol
  ≥65 years with high VTE risk
    Intention to treat
    Per protocol
Caprini risk assessment
  Low-high
    Intention to treat
    Per protocol
  Highest
    Intention to treat
    Per protocol
0.30 (-0.65 to 1.26)
0.01 (-1.63 to 1.65)
0.22 (-0.62 to 1.06)
0.25 (-0.75 to 1.26)
0.09 (-1.56 to 1.74)
-0.55 (-3.45 to 2.35)
0.34 (-1.15 to 1.82)
0.42 (-1.43 to 2.28)
0.27 (-1.09 to 1.64)
-0.19 (-2.35 to 1.96)
-3-4 -2 -1 1 20 3 4
VTE risk  
Favours
LMWH
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LMWH + GCS
Effect estimate
(95% CI)
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(95% CI)
<0.001
<0.001
<0.001
<0.001
<0.001
0.003
<0.001
0.001
<0.001
<0.001
P
value
Fig 2 | Venous thromboembolism (VTE) for overall population and subpopulations with high VTE risk (Department 
of Health (DoH) risk assessment tool5) and all populations (Caprini VTE risk assessment7). Data are effect estimates 
in percentages. Dashed vertical line is the non-inferiority margin (3.5%). GCS=graduated compression stockings; 
LMWH=low molecular weight heparin
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pharmacological measures are not contraindicated 
and are given.8 21 In our study population, 854/892 
(95.7%) participants received below knee stockings, 
which probably reflects UK practice. This study cannot 
absolutely conclude that thigh length GCS have no 
benefit. However, in a randomised controlled trial 
of inpatients with acute stroke, thigh length GCS 
did not significantly reduce the risk of developing 
femoro-popliteal deep vein thrombosis with or without 
symptoms,9 and were associated with more skin 
complications. These findings resulted in a reduction 
in the use of GCS in patients with stroke.
The findings of this study are supported by data 
from a single centre where the policy has been not 
to use GCS in patients receiving elective surgery who 
are given a thromboprophylactic dose of LMWH. VTE 
outcomes reported by this centre are comparable to 
national figures.22
Meaning of the study
A 15.4% reduction in 90 day VTE mortality has recently 
been reported since the introduction of a systematic 
approach to preventing hospital associated VTE in 
the UK in 2010.23 An opinion states that “we have 
entered an era in which the rates of VTE after surgery 
have fallen significantly through improved care and 
pharmaco-thromboprophylaxis such that combined 
thromboprophylaxis using LMWH and GCS might no 
longer be necessary.”23
It is notable that in this study event rates were much 
lower than expected based on previously published 
studies.10 These rates could be partly attributed to 
shorter lengths of stay, improved operative techniques, 
and analgesic regimens that allow earlier mobilisation. 
It is clear that current guidelines are largely based on 
historical data and should be revisited.
The findings of this study will probably have 
clinical implications on the administration of GCS 
in patients undergoing elective surgical procedures. 
Initial estimates of the annual cost of purchasing and 
applying GCS to surgical patients assessed as being 
at moderate or high risk of VTE exceeded £63m in 
England ($79m; €72m).12 A substantial reduction of 
these costs, scaled globally and on a recurring basis, 
has the potential to have a major positive financial 
impact on hospital healthcare systems.
In conclusion, this multicentre randomised trial 
showed that LMWH alone is non-inferior to LMWH and 
GCS for the prevention of VTE in patients undergoing 
elective surgery who are at moderate or high risk of 
Table 3 | Quality of life outcomes and compliance in overall population
Quality of life and compliance LMWH (n=948) LMWH+GCS (n=940) Mean difference (95% CI)† P value
Received surgery (LMWH n=937, LMWH+GCS n=921)
EQ-5D-5L (No; mean (SD))
 Baseline 933; 0.825 (0.185) 910; 0.818 (0.192) — —
 1 week or discharge 874; 0.648 (0.232) 839; 0.627 (0.244) 0.015 (−0.004 to 0.033) 0.12
 14-21 days 846; 0.788 (0.202) 820; 0.773 (0.206) 0.011 (−0.008 to 0.030) 0.25
 90 days 774; 0.856 (0.192) 743; 0.843 (0.197) 0.011 (−0.009 to 0.031) 0.27
EQ-5D VAS (No; mean (SD))
 Baseline 932; 77.0 (17.4) 907; 77.0 (18.2) — —
 1 week or discharge 873; 68.2 (19.5) 837; 67.8 (20.1) 0.23 (−1.32 to 1.79) 0.77
 14-21 days 846; 77.4 (17.4) 819; 77.2 (17.0) −0.04 (−1.62 to 1.54) 0.96
 90 days 773; 80.2 (17.9) 743; 80.7 (18.2) −0.29 (−1.94 to 1.37) 0.73
Compliance with GCS* (No (%)) 37 (4.0) 750 (81.4) (−0.04 to 0.18) —
Compliance with LMWH (No (%))
 Received all prescribed LMWH doses 768 (82.0) 755 (82.0) (−0.81 to 0.19) —
 Received ≥50% of prescribed doses 779 (83.1) 762 (82.7) (−0.82 to 0.18) —
EQ-5D-5L=EuroQol five dimensions five levels; EQ-5D VAS=EuroQol five dimensions visual analogue scale; GCS=graduated compression stockings; 
LMWH=low molecular weight heparin.
*Stockings worn for 75% of total admission time.
†Non-parametric bounds for average causal effect for compliance outcome.
Table 4 | Complications and all cause mortality in overall population as treated. Values are numbers (percentages) or 
numbers
Complications and mortality LMWH (n=779) LMWH+GCS (n=787) GCS only (n=160) Neither (n=132)
GCS related complications* 2 (0.3)† 50 (6.4) 5 (3.1) 1 (0.8)†
 Discomfort 2 41 4 1
 Skin break or ulcer 0 1 0 0
 Skin rash 0 4 0 0
 Other 0 21 1 0
Adverse reactions to LMWH* 6 (0.8) 2 (0.3) 0 0
 Abnormal liver enzyme 7 0 0 0
 Other 2 2 0 0
Bleeding complications 5 (0.6) 4 (0.5) 1 (0.6) 0
All cause mortality 2 (0.3) 0 0 1 (0.8)
GCS=graduated compression stockings; LMWH=low molecular weight heparin.
A proportion of participants had treatment that was outside the treatment to which they were randomised (“GCS only” and “Neither” columns; “Neither” 
indicates that they received neither LMWH nor GCS).
*Participants could have more than one complication.
†Participants wore stockings for less than an hour, therefore classified as not wearing stockings.
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VTE. Non-inferiority was shown across individual 
risk subpopulations. If we consider the potential 
adverse events and cost of GCS, urgent revision of 
national and international VTE prevention guidelines 
is recommended.
Unanswered questions and future research
We excluded patients in whom current evidence 
supports pharmacological VTE prophylaxis after 
discharge from hospital,1 24 such as those undergoing 
major joint replacement surgery or abdominopelvic 
cancer resections. This exclusion should be considered 
when translating and implementing the findings of 
this study into clinical practice. Further studies are 
needed to evaluate the adjuvant benefit of GCS in these 
groups of patients and in those undergoing surgery in 
the emergency setting.
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